share_log

HC Wainwright & Co. Maintains Buy on Biotricity, Lowers Price Target to $2

Benzinga Real-time News ·  Jul 15, 2022 06:24

HC Wainwright & Co. analyst Kevin Dede maintains Biotricity (NASDAQ:BTCY) with a Buy and lowers the price target from $6 to $2.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment